All In Biotech

NDA 017624 · Baxter Hlthcare

Forane

Isoflurane · Inhalation · General Anesthetic

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Dec 9, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1979

Dec 18, 1979

Approved uses

2

Original approval plus efficacy supplements

Registered trials

146

27 Phase 3, 11 recruiting

FAERS reports

1,965

1,845 serious, 299 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 9, 2024.

FORANE (isoflurane, USP) may be used for induction and maintenance of general anesthesia. Adequate data have not been developed to establish its application in obstetrical anesthesia. FORANE, a general anesthetic, is an inhalation agent indicated for induction and maintenance of general anesthesia. ( 1 )

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 22, 1982 Supplement 7 · Efficacy
  • Dec 18, 1979 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
  • FORANE · ISOFLURANE 99.9% · LIQUID, INHALATION · Prescription · TE AN

Clinical trials

Interventional ClinicalTrials.gov studies with "Isoflurane" as an intervention, any sponsor and status, largest first.

All 146 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • hypotension238
  • drug ineffective181
  • renal failure158
  • pain149
  • injury136
  • drug interaction129
  • anxiety128
  • unevaluable event123
  • off label use115
  • hyperthermia malignant114
  • fear110
  • emotional distress103

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200479
200567
200655
200768
200898
200969
201088
2011245
201276
201378
201457
201585
201683
201786
201889
201995
2020104
202194
202258
202382
202456
202575
202674

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,634 on PubMed

Sponsor: Baxter Hlthcare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.